Cargando…

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

OBJECTIVE: To characterise the molecular pathways impacted by the pharmacologic effects of the Janus kinase (JAK) 1 and JAK2 inhibitor baricitinib in SLE. METHODS: In a phase II, 24-week, randomised, placebo-controlled, double-blind study (JAHH), RNA was isolated from whole blood in 274 patients and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dörner, Thomas, Tanaka, Yoshiya, Petri, Michelle A, Smolen, Josef S, Wallace, Daniel J, Dow, Ernst R, Higgs, Richard E, Rocha, Guilherme, Crowe, Brenda, Benschop, Robert J, Byers, Nicole L, Silk, Maria E, de Bono, Stephanie, Fantini, Damiano, Hoffman, Robert W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical Trials and Drug Discovery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549481/ https://www.ncbi.nlm.nih.gov/pubmed/33037080 http://dx.doi.org/10.1136/lupus-2020-000424

Ejemplares similares

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
por: Urowitz, Murray B, et al.
Publicado: (2015)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
por: Jin, Hui-Zhi, et al.
Publicado: (2023)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
por: van Vollenhoven, Ronald F, et al.
Publicado: (2018)

The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
por: Gracia-Tello, Borja, et al.
Publicado: (2017)

Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
por: Jiang, Nan, et al.
Publicado: (2022)

Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study
por: Mahran, Safaa A, et al.
Publicado: (2021)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study
por: Lu, Wentian, et al.
Publicado: (2022)

Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE)
por: Nasonov, E, et al.
Publicado: (2015)

Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus
por: Sullivan, B A, et al.
Publicado: (2016)

Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE
por: Kamen, Diane L, et al.
Publicado: (2022)

Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study
por: Furie, Richard, et al.
Publicado: (2016)

Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis
por: Tian, Jingru, et al.
Publicado: (2018)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study
por: Furie, Richard A, et al.
Publicado: (2017)

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
por: Arriens, Cristina, et al.
Publicado: (2020)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
por: Dörner, Thomas, et al.
Publicado: (2022)

A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus
por: Li, Yupeng, et al.
Publicado: (2019)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Lack of Evidence for Blood Pressure Effects of Caffeine Added to Ibuprofen
por: Lampert, Anette, et al.
Publicado: (2023)

Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents
por: Lougheed, Kathryn E.A., et al.
Publicado: (2011)

Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
por: Barr, David A., et al.
Publicado: (2016)

Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana
por: Otchere, I.D., et al.
Publicado: (2016)

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
por: Zhang, Xiaolong, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
por: Kawata, Yoshiko, et al.
Publicado: (2020)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
por: Yokogawa, Tatsushi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_339iju9ccj5h80otu2fhj9s5o3